DDInter1266 DDInter1725
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
Naproxen {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) resembles {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Naproxen {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) resembles {v} (Disease) ulcerative colitis
ulcerative colitis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Naproxen (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Sulfasalazine (Compound)
Naproxen (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Sulfasalazine (Compound)
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulfasalazine (Compound) and PTGS2 (Gene) is upregulated by Sulfasalazine (Compound)
Naproxen (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) resembles Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Sulfasalazine (Compound)
Naproxen (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Olsalazine (Compound) and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Olsalazine (Compound) and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Naproxen (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) resembles ulcerative colitis (Disease) and ulcerative colitis (Disease) is treated by Sulfasalazine (Compound)